🚀 VC round data is live in beta, check it out!
ProKidney Valuation Multiples
Discover revenue and EBITDA valuation multiples for ProKidney and similar public comparables like Foghorn Therapeutics, Artiva Biotherapeutics, Animalcare Group, AC Immune and more.
ProKidney Overview
About ProKidney
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Founded
2021
HQ
Employees
204
Website
Sectors
Financials (LTM)
EV
$43M
ProKidney Financials
ProKidney reported last 12-month revenue of $717K and negative EBITDA of ($161M).
In the same LTM period, ProKidney generated $717K in gross profit, ($161M) in EBITDA losses, and had net loss of ($85M).
Revenue (LTM)
ProKidney P&L
In the most recent fiscal year, ProKidney reported revenue of $893K and EBITDA of ($145M).
ProKidney expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $717K | XXX | $893K | XXX | XXX | XXX |
| Gross Profit | $717K | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($161M) | XXX | ($145M) | XXX | XXX | XXX |
| EBITDA Margin | (22459%) | XXX | (16195%) | XXX | XXX | XXX |
| EBIT Margin | (23557%) | XXX | (18005%) | XXX | XXX | XXX |
| Net Profit | ($85M) | XXX | ($69M) | XXX | XXX | XXX |
| Net Margin | (11909%) | XXX | (7725%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ProKidney Stock Performance
ProKidney has current market cap of $309M, and enterprise value of $43M.
Market Cap Evolution
ProKidney's stock price is $2.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $43M | $309M | -0.5% | XXX | XXX | XXX | $-0.49 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialProKidney Valuation Multiples
ProKidney trades at 60.6x EV/Revenue multiple, and (0.3x) EV/EBITDA.
EV / Revenue (LTM)
ProKidney Financial Valuation Multiples
As of April 19, 2026, ProKidney has market cap of $309M and EV of $43M.
Equity research analysts estimate ProKidney's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ProKidney has a P/E ratio of (3.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $309M | XXX | $309M | XXX | XXX | XXX |
| EV (current) | $43M | XXX | $43M | XXX | XXX | XXX |
| EV/Revenue | 60.6x | XXX | 48.7x | XXX | XXX | XXX |
| EV/EBITDA | (0.3x) | XXX | (0.3x) | XXX | XXX | XXX |
| EV/EBIT | (0.3x) | XXX | (0.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 60.6x | XXX | — | XXX | XXX | XXX |
| P/E | (3.6x) | XXX | (4.5x) | XXX | XXX | XXX |
| EV/FCF | (0.3x) | XXX | (0.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ProKidney Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
ProKidney Margins & Growth Rates
ProKidney's revenue in the last 12 month declined by (58%).
ProKidney's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.8M for the same period.
ProKidney's rule of 40 is (57461%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ProKidney's rule of X is (57560%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
ProKidney Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (58%) | XXX | (66%) | XXX | XXX | XXX |
| EBITDA Margin | (22459%) | XXX | (16195%) | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 21% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (57461%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (57560%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7582% | XXX | 5799% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 16913% | XXX | 12780% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 18578% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ProKidney Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ProKidney | XXX | XXX | XXX | XXX | XXX | XXX |
| Foghorn Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Artiva Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Animalcare Group | XXX | XXX | XXX | XXX | XXX | XXX |
| AC Immune | XXX | XXX | XXX | XXX | XXX | XXX |
| Duopharma Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ProKidney M&A Activity
ProKidney acquired XXX companies to date.
Last acquisition by ProKidney was on XXXXXXXX, XXXXX. ProKidney acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ProKidney
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialProKidney Investment Activity
ProKidney invested in XXX companies to date.
ProKidney made its latest investment on XXXXXXXX, XXXXX. ProKidney invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ProKidney
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ProKidney
| When was ProKidney founded? | ProKidney was founded in 2021. |
| Where is ProKidney headquartered? | ProKidney is headquartered in United States. |
| How many employees does ProKidney have? | As of today, ProKidney has over 204 employees. |
| Who is the CEO of ProKidney? | ProKidney's CEO is Bruce Culleton. |
| Is ProKidney publicly listed? | Yes, ProKidney is a public company listed on Nasdaq. |
| What is the stock symbol of ProKidney? | ProKidney trades under PROK ticker. |
| When did ProKidney go public? | ProKidney went public in 2022. |
| Who are competitors of ProKidney? | ProKidney main competitors are Foghorn Therapeutics, Artiva Biotherapeutics, Animalcare Group, AC Immune. |
| What is the current market cap of ProKidney? | ProKidney's current market cap is $309M. |
| What is the current revenue of ProKidney? | ProKidney's last 12 months revenue is $717K. |
| What is the current revenue growth of ProKidney? | ProKidney revenue growth (NTM/LTM) is (58%). |
| What is the current EV/Revenue multiple of ProKidney? | Current revenue multiple of ProKidney is 60.6x. |
| Is ProKidney profitable? | No, ProKidney is not profitable. |
| What is the current EBITDA of ProKidney? | ProKidney has negative EBITDA and is not profitable. |
| What is ProKidney's EBITDA margin? | ProKidney's last 12 months EBITDA margin is (22459%). |
| What is the current EV/EBITDA multiple of ProKidney? | Current EBITDA multiple of ProKidney is (0.3x). |
| What is the current FCF of ProKidney? | ProKidney's last 12 months FCF is ($162M). |
| What is ProKidney's FCF margin? | ProKidney's last 12 months FCF margin is (22530%). |
| What is the current EV/FCF multiple of ProKidney? | Current FCF multiple of ProKidney is (0.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.